Rman E. Inhibition of NF-kappaB induces apoptosis of KSHVinfected main effusion lymphoma cells. Blood. 2000; 96:2537?542. [PubMed: 11001908] 21. Hughes DJ, Wood JJ, Jackson BR, et al. NEDDylation is crucial for Kaposi’s sarcoma-associated herpesvirus latency and lytic reactivation and represents a novel anti-KSHV target. PLoS Pathog. 2015; 11:e1004771. [PubMed: 25794275] ** The ubiquitin ligase, NEDD8, has emerged as interesting therapeutic target, in part, for the improvement of a new inhibitor of NEDD8 activation. Inhibition of NEDD8 activity causes principal effusion lymphoma cytotoxicity and other literature suggests that this pathway may be a crucial target for other viral infections, which includes HIV. 22. Tomlinson CC, Damania B. The K1 protein of Kaposi’s sarcoma-associated herpesvirus activates the Akt signaling pathway. J Virol. 2004; 78:1918?927. [PubMed: 14747556] 23. Sodhi A, Chaisuparat R, Hu J, et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell. 2006; 10:133?43. [PubMed: 16904612] 24. Morris VA, Punjabi AS, Lagunoff M. Activation of Akt via gp130 receptor signaling is needed for Kaposi’s sarcoma-associated herpesvirus-induced lymphatic reprogramming of endothelial cells. J Virol. 2008; 82:8771?779. [PubMed: 18579585] 25. Roy D, Sin SH, Lucas A, et al. mTOR inhibitors block Kaposi sarcoma growth by inhibiting vital autocrine growth components and tumor angiogenesis. Cancer Res. 2013; 73:2235?246. [PubMed: 23382046] 26. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med. 2005; 352:1317?323. [PubMed: 15800227] 27. Godfrey A, Anderson J, Papanastasiou A, et al. Inhibiting key effusion lymphoma by lentiviral vectors encoding short hairpin RNA. Blood. 2005; 105:2510?518. [PubMed: 15572586] 28. Boss IW, Nadeau PE, Abbott JR, et al.6-Bromo-5-chloroimidazo[1,2-a]pyridine site A Kaposi’s sarcoma-associated herpesvirus-encoded ortholog of microRNA miR-155 induces human splenic B-cell expansion in NOD/LtSz-scid IL2Rgammanull mice. J Virol. 2011; 85:9877?886. [PubMed: 21813606] 29. Gottwein E, Cullen BR. A human herpesvirus microRNA inhibits p21 expression and attenuates p21-mediated cell cycle arrest. J Virol. 2010; 84:5229?237. [PubMed: 20219912] 30. Kieffer-Kwon P, Happel C, Uldrick TS, et al. KSHV MicroRNAs Repress Tropomyosin 1 and Increase Anchorage-Independent Growth and Endothelial Tube Formation. PLoS 1. 2015; ten:e0135560. [PubMed: 26263384] 31. Moody R, Zhu Y, Huang Y, et al. KSHV microRNAs mediate cellular transformation and tumorigenesis by redundantly targeting cell growth and survival pathways. PLoS Pathog. 2013; 9:e1003857. [PubMed: 24385912] 32.15418-29-8 Price Friborg J Jr, Kong W, Hottiger MO, et al.PMID:23664186 p53 inhibition by the LANA protein of KSHV protects against cell death. Nature. 1999; 402:889?94. [PubMed: 10622254] 33. Sarek G, Kurki S, Enback J, et al. Reactivation in the p53 pathway as a therapy modality for KSHV-induced lymphomas. J Clin Invest. 2007; 117:1019?028. [PubMed: 17364023]Author Manuscript Author Manuscript Author Manuscript Author ManuscriptCurr Opin HIV AIDS. Author manuscript; readily available in PMC 2018 December 31.Goncalves et al.Page34. An J, Sun Y, Sun R, et al. Kaposi’s sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role with the NF-kappaB and JNK/AP1 pathways. Oncogene. 2003; 22:3371?3385. [PubMed: 12776188] 35. Monini P, Colombini S,.